AMRI reports ‘solid’ results for Q2

Published: 2-Aug-2012
Manufacturing Finance

Large-scale manufacturing drives growth


AMRI reported ‘solid’ financial and operating results for the second quarter to 30 June, including a US$2.2m improvement in net income compared with Q2 2011.

The US contract manufacturer’s large-scale manufacturing segment continues to drive growth and its aseptic formulation and fill operations in Burlington, US also showed improvement during the quarter.

AMRI’s total contract revenue, from discovery services, development and small-scale and large-scale manufacturing, declined during the quarter by 2% to US$42.4m, compared with the same period in 2011.

Highlights include a winning a contract with Cardium Therapeutics to manufacture sterile pre-filled syringes in support of the US introduction of Excellagen and the expansion of its global medicinal and computational chemistry capabilities in India, complementing existing capabilities in the US and Singapore.

  • Companies:
  • Curia
See more

You may also like

Manufacturing

Curia recognised on India Pharma Outlook’s 2023 List of top 10 CDMO companies

Read more
Curia, a leading contract research, development and manufacturing organisation, has been recognised as one of the top 10 CDMOs in India by India Pharma Outlook

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  2. Key considerations when investing in an air compressor When choosing an air compressor, many factors should be taken into consideration, including initial cost, maintenance requirements and energy efficiency
  3. RCPE and InSilicoTrials to digitalise and accelerate the development of pharmaceutical manufacturing processes RCPE and InSilicoTrials have agreed to an exclusive partnership to commercialise the XPS simulation software. Specifically developed for pharmaceutical applications, XPS allows companies to assess their process configurations in unprecedented detail and explore the decision space without time- and labour-intensive experiments
  4. Ascend acquires GMP manufacturing site from Beacon Therapeutics The acquisition also incorporates a long-term partnership with Beacon to continue the manufacturing of its products for clinical use
  5. Tabletability, compactability and compressibility: What’s the difference? To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be complicated. Here, the tablet experts Natoli explain how to develop tabletability, compactibility, and compressibility profiles

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Manufacturing

Curia recognised on India Pharma Outlook’s 2023 List of top 10 CDMO companies

Curia, a leading contract research, development and manufacturing organisation, has been recognised as one of the top 10 CDMOs in India by India Pharma Outlook
Manufacturing

Curia wins 2023 Frost & Sullivan Customer Value Leadership Award

The company was recognised in providing a best-in-class customer experience in the CRDMO industry through its innovative approach and growth strategy
Manufacturing

Curia reveals continuous-flow collaboration with Corning

Continuous flow chemistry is critical for the development and manufacture of pharmaceutical intermediates and APIs
Manufacturing

Curia adopts the Berkeley Lights platform

The partnership will expand its antibody discovery capabilities
Manufacturing

Curia enters cooperative agreement with US government to expand sterile fill-finish capability

Curia, formerly AMRI, a leading contract research, development and manufacturing organisation, announces a cooperative agreement with the Biomedical Advanced Research and Development Authority (BARDA), part of the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR), the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) and the US Army Contracting Command to support the domestic production of injectable medicines
Manufacturing

US government to support Curia fill-finish expansion

“This agreement assures our ability to meet urgent demands for the supply of critical medicines well into the future,” said Curia Chairman and CEO, John Ratliff
Manufacturing

Curia unveils comprehensive mRNA solution

Curia’s mRNA services combine comprehensive experience and flexible capabilities from discovery through fill-finish manufacturing
Subscribe now